What Arctic Therapeutics does

Arctic Therapeutics (ATx) is a privately held, clinical-stage biopharmaceutical company founded in 2015 by Dr. Hakon Hakonarson as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia. Headquartered in Reykjavík, Iceland, with clinical operations in Akureyri and a commercial presence in Philadelphia, the company applies genomics to discover and develop small-molecule and peptide therapies for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. Its discovery engine combines Iceland's nationwide genealogy database, a government-licensed biobank, national hospital Electronic Health Records, and in-house genotyping/sequencing operations, layered onto the founder-built pediatric genomic biobank at CAG/CHOP.

The company has five mechanistically distinct pipeline programs. The lead asset AT-001 is an oral small-molecule designed to prevent and dissolve amyloid plaques and tau tangles, in development for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease; an enhanced derivative NACA (NAC-amide) shows >10-fold higher potency than parent NAC in vitro. AT-004 is a topical acetylcholinesterase inhibitor targeting the non-neuronal cholinergic anti-inflammatory pathway in skin, with acne vulgaris as the lead indication and planned expansion to atopic dermatitis, psoriasis, and rosacea. Three earlier-stage programs round out the pipeline: AT-002 (SOCS1 KIR-domain peptide mimetic / JAK-STAT inhibitor for autoimmune disease), AT-003 (CLEC16A-targeted autophagy/mitophagy modulator), and AT-005 (RV-C / CDHR3 antagonist for severe asthma). AT-001 holds EMA Orphan Drug Designation in HCCAA and has EMA approval for Phase IIb/III (HCCAA) and Phase IIa (Alzheimer's); AT-004 is in a Phase IIa trial in Denmark with first patients enrolled in February 2026.

Arctic Therapeutics is pre-revenue and does not sell products commercially. Its operating model is funded by venture capital (€26.5M oversubscribed Series A closed January 2025, plus prior EIC Accelerator blended finance of approximately $13.3M in 2022/2023) and non-dilutive EIC grants. Clinical execution is outsourced to specialist CROs — Blueskin (a Sanos Group entity) for dermatology and NeuroScios (also Sanos Group) for CNS — with the Sanos CEO joining ATx's board. The planned revenue model is out-licensing and co-development of lead assets to large pharma partners, supported by an in-house business development function led by CBO/General Counsel Lisa DeMarco (ex-GSK). Geographic reach spans Iceland, Denmark, the broader EU clinical/regulatory ecosystem, and the United States.

Name

Arctic Therapeutics

Legal name

Arctic Therapeutics

Website

https://arctictherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Arctic Therapeutics is an Icelandic clinical-stage biopharmaceutical company that applies genomics — leveraging Iceland's nationwide genealogy database and a licensed biobank — to discover and develop small-molecule and peptide therapies for dementia (AT-001), inflammatory skin diseases (AT-004), and autoimmune and respiratory conditions.

Ownership category

akta.pro rank

Product category

Drug Discovery & Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)

akta.pro secondary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Drug discovery development
• Genomic drug discovery
• Clinical stage biopharmaceuticals
• Small molecule therapeutics
• Inflammatory disease treatments

Headquarters

HQ city

Reykjavík

HQ country

Iceland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture equity financing (Series A and earlier): Pre-revenue clinical-stage biopharma funded by venture capital. Closed a €26.5M oversubscribed Series A in January 2025 from EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, Kerecis consortium and Chemometec. Prior EIC Accelerator blended finance included grant and equity (2022, $13.3M).
2. Non-dilutive grant funding: European Innovation Council (EIC) Accelerator grant for clinical development of AT-001; multi-million euro value. Used to support Phase II development of dementia/Alzheimer's candidate.
3. Future drug commercialization (planned): Planned revenue from out-licensing and co-development of lead assets AT-001 and AT-004. CBO/GC Lisa DeMarco is responsible for IP strategy, commercial, out-licensing and co-development efforts. No product sales yet.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Arctic Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and peptide drug candidates for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma, built on an applied genomics platform that leverages Iceland's nationwide genealogy database and a government-licensed biobank. Its two lead programs are AT-001, an oral amyloid-aggregation disruptor in Phase II trials for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease, and AT-004, a topical acetylcholinesterase inhibitor in Phase IIa for acne vulgaris. Revenue is expected to come from out-licensing and co-development of these assets with large pharmaceutical partners.

Product overview

Arctic Therapeutics is a clinical-stage biopharmaceutical company with a diversified pipeline of five investigational therapeutic programs (AT-001, AT-002, AT-003, AT-004, and AT-005) targeting rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. AT-001 (oral small-molecule therapy for dementia) and AT-004 (topical therapy for inflammatory skin diseases) are the two lead clinical-stage programs currently in Phase II trials, while AT-002 (autoimmune/inflammatory diseases), AT-003 (CLEC16A-linked diseases), and AT-005 (severe asthma) are at earlier stages of development. The portfolio is built on applied genomics and was established as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, leveraging Iceland's nationwide genealogy database and biobank.

Differentiator

Problem solved

Functional benefit

Products and services

• AT-001 AT-001 is an oral small-molecule therapy designed to address rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles through destabilization of the inter/intra-molecular interactions that form and maintain these aggregates. It is being evaluated in hereditary cystatin C amyloid angiopathy (HCCAA), Alzheimer's disease, and other protein aggregation disorders, with multi-analyte biomarker readouts (Simoa pTau217/total Tau, NfL, SOBA toxic oligomers, MRI, PET).
• AT-004 AT-004 is a topical acetylcholinesterase inhibitor engineered to treat inflammatory skin diseases, with lead indication acne vulgaris. It targets the non-neuronal cholinergic system to modulate the cholinergic anti-inflammatory pathway and regulate pro-inflammatory cytokines such as TNF-α, with planned expansion into atopic dermatitis, psoriasis, and rosacea.
• AT-002 AT-002 is a peptide mimetic of the KIR domain of SOCS1 acting as a potent JAK-STAT pathway inhibitor. It is in development for autoimmune uveitis and other autoimmune/inflammatory diseases such as lupus, psoriasis, juvenile dermatomyositis, and cytokine storm syndromes arising from CAR-T immunotherapy or COVID infection.
• AT-003 AT-003 is a small-molecule mitophagy and autophagy modulator designed to counteract aberrant CLEC16A activity, which has been linked to 16 autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, as well as Parkinson's disease.
• AT-005 AT-005 is a novel therapeutic approach to prevent severe asthma attacks by targeting the C strain of Rhinovirus (RV-C), the most common trigger of these exacerbations in allergic asthma, by blocking the interaction of RV-C with its entry receptor CDHR3.

Quantifiable outcome

• Closed €26.5M oversubscribed Series A financing from international investor syndicate (Jan 2025)
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered flagship and core.

• Sanos GroupflagshipStrategic or Co-development PartnerInvestcorp-backed multi-niche CRO with ~200 employees in dermatology, CNS (via NeuroScios), and osteoarthritis. CEO Jeppe Ragnar Andersen joined ATx's board of directors as part of the Series A. Sanos entity Blueskin is conducting the Phase IIa AT-004 trial in Denmark. NeuroScios (Sanos subsidiary) supports AT-001 Alzheimer's program.
• Cerebrum DAOcoreStrategic or Co-development PartnerSwiss-based DAO focused on translational neuroscience for dementia. Participated in the Series A. Dr. Maryna Polyakova (Translational Neuroscience Lead at Cerebrum DAO) serves as an advisor to ATx.
• Children's Hospital of Philadelphia / Center for Applied Genomics (CAG)flagshipStrategic or Co-development PartnerATx is a 2015 spin-off from CAG; maintains close research relationships with CHOP and licenses intellectual property from CHOP. CAG is the largest pediatric biobank and genomic database in the world, founded by ATx's founder in 2006. Dr. Elizabeth J.K. Bhoj (CHOP Division of Human Genetics) serves as an advisor.
• Blueskin (Sanos Group)coreImplementation/ SI/ Consulting PartnerEuropean CRO specializing in dermatology, part of Sanos Group. Conducting the Phase IIa trial of topical AT-004 in acne vulgaris across three clinical sites in Denmark (60 participants over 12 weeks).
• Landspitali University Hospital (Iceland)coreImplementation/ SI/ Consulting PartnerHosted the open-label Phase 2a clinical trial of NAC in HCCAA carriers between March 2019 and December 2021; 17 L68Q-CST3 mutation carriers enrolled. Hospital also serves as a site for the AT-001 Phase IIa study in Alzheimer's.
• NeuroScios (Sanos Group portfolio company)coreStrategic or Co-development PartnerAustrian CRO specializing in Alzheimer's and CNS diseases, founded by Dr. Manfred Windisch; NeuroScios is a Sanos Group portfolio company. Supports AT-001 Alzheimer's clinical development. Dr. Manfred Windisch (NeuroScios CEO) serves as advisor to ATx.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Anavex Life Sciences: Clinical-stage biopharma developing small molecules for Alzheimer's, Parkinson's, and rare neurological diseases including Rett syndrome. Comparable to Arctic Therapeutics' small-molecule, CNS-focused, clinical-stage asset profile targeting dementia and orphan neuro indications.
• AC Immune: Clinical-stage Swiss biopharma developing first-in-class therapeutics for neurodegenerative diseases including Alzheimer's and rare dementia, with multiple programs targeting amyloid, tau, and neuroinflammation. Directly comparable to Arctic Therapeutics' AT-001 amyloid-disruption approach and dementia focus.
• Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration with genetically validated targets and BBB-penetrant small molecules. Comparable to Arctic Therapeutics on genomics-driven CNS drug discovery and the strategy of leveraging genetic insights for first-in-class neurodegenerative therapeutics.
• Arcutis Biotherapeutics: Late-stage commercial dermatology biopharma with topical small-molecule treatments for inflammatory skin diseases including atopic dermatitis, seborrheic dermatitis, and psoriasis. Directly comparable to Arctic Therapeutics' AT-004 topical anti-inflammatory platform targeting acne vulgaris and adjacent dermatology indications.
• Prothena Corporation: Clinical-stage biotech developing protein-misfolding and amyloid-targeted therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Directly comparable mechanism space to AT-001 (amyloid/tau disruption) and similar small-cap, clinical-stage biopharma profile.
• Cassava Sciences: Clinical-stage biopharma developing simufilam for Alzheimer's disease. Comparable clinical-stage, CNS-focused, small-molecule Alzheimer's drug developer with similar market capitalization profile and Phase II/III clinical execution model.

Broad incumbents

• BioMarin Pharmaceutical: Established commercial rare-disease biopharma with multiple approved enzyme-replacement and gene therapies. Comparable to Arctic Therapeutics' orphan-drug strategy in HCCAA and its rare-disease regulatory pathway, though at a far larger scale and with commercial products.
• Alnylam Pharmaceuticals: Established commercial biopharma pioneering RNAi-based therapeutics, founded on genomics-driven target discovery. Comparable to Arctic Therapeutics on the genomics-first drug discovery paradigm and the early-stage-to-commercial trajectory via platform technology.
• Sage Therapeutics: CNS-focused biopharma (acquired by Biogen in 2024) developing CNS therapeutics for depression and neurological disorders. Comparable to Arctic Therapeutics on CNS drug development, clinical execution via CRO partners, and small-molecule CNS drug discovery.

Emerging players

• Prilenia Therapeutics: Clinical-stage biotech developing pridopidine for Huntington's disease and ALS. Comparable to Arctic Therapeutics as a small, clinical-stage CNS biopharma with genetically validated neuro targets pursuing orphan or rare-disease CNS indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/arctic-therapeutics-at

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arctic Therapeutics